These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37924275)

  • 1. Shedding light on data monitoring committee charters on ClinicalTrials.gov.
    Fine AM; Golfinopoulos E; Tse T
    Clin Trials; 2024 Apr; 21(2):260-261. PubMed ID: 37924275
    [No Abstract]   [Full Text] [Related]  

  • 2. Bringing data monitoring committee charters into the sunlight.
    DeMets DL; Zarin DA; Rockhold F; Ellenberg SS; Fleming T; Wittes J
    Clin Trials; 2023 Aug; 20(4):447-451. PubMed ID: 37231737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Case for Access to Data Monitoring Committee Charters.
    Zarin D; Wittes JT; Fleming TR; Rockhold F; Ellenberg S; DeMets DL
    NEJM Evid; 2024 Sep; 3(9):EVIDctw2400058. PubMed ID: 39189859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative.
    Calis KA; Archdeacon P; Bain R; DeMets D; Donohue M; Elzarrad MK; Forrest A; McEachern J; Pencina MJ; Perlmutter J; Lewis RJ
    Clin Trials; 2017 Aug; 14(4):342-348. PubMed ID: 28503947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Commentary on DeMets et al: The need for greater transparency regarding data monitoring committee charters.
    Shah SK; Eckstein L; Ibrahim A
    Clin Trials; 2023 Aug; 20(4):452-454. PubMed ID: 37231704
    [No Abstract]   [Full Text] [Related]  

  • 6. Data monitoring committees: Promoting best practices to address emerging challenges.
    Fleming TR; DeMets DL; Roe MT; Wittes J; Calis KA; Vora AN; Meisel A; Bain RP; Konstam MA; Pencina MJ; Gordon DJ; Mahaffey KW; Hennekens CH; Neaton JD; Pearson GD; Andersson TL; Pfeffer MA; Ellenberg SS
    Clin Trials; 2017 Apr; 14(2):115-123. PubMed ID: 28359194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Data Monitoring Committees: Current issues.
    Fleming TR; Ellenberg SS; DeMets DL
    Clin Trials; 2018 Aug; 15(4):321-328. PubMed ID: 29629815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the functions and operations of data monitoring committees: Survey and focus group findings.
    Calis KA; Archdeacon P; Bain RP; Forrest A; Perlmutter J; DeMets DL
    Clin Trials; 2017 Feb; 14(1):59-66. PubMed ID: 27885056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liability issues for data monitoring committee members.
    DeMets DL; Fleming TR; Rockhold F; Massie B; Merchant T; Meisel A; Mishkin B; Wittes J; Stump D; Califf R
    Clin Trials; 2004; 1(6):525-31. PubMed ID: 16279293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Data monitoring committee interim reports: We must get there soon!
    DeMets DL; Wittes J
    Clin Trials; 2022 Feb; 19(1):107-111. PubMed ID: 34693741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in Data Monitoring Committees, Randomization, and Blinding in Cardiovascular Disease Studies on ClinicalTrials.gov from 2012 to 2021.
    Rawlley B; Bansal K; Dayal U; Julka D; Salooja I; Sanchez AC; Gupta K; Kumar S; Chaudhuri D
    Am J Cardiol; 2023 Oct; 205():10-11. PubMed ID: 37579654
    [No Abstract]   [Full Text] [Related]  

  • 12. Data monitoring committees for pragmatic clinical trials.
    Ellenberg SS; Culbertson R; Gillen DL; Goodman S; Schrandt S; Zirkle M
    Clin Trials; 2015 Oct; 12(5):530-6. PubMed ID: 26374679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A third trial oversight committee: Functions, benefits and issues.
    Lane JA; Gamble C; Cragg WJ; Tembo D; Sydes MR
    Clin Trials; 2020 Feb; 17(1):106-112. PubMed ID: 31665920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Committee for Medicinal Products for Human Use (CHMP) guideline on Data Monitoring Committees.
    ; ;
    Stat Med; 2006 May; 25(10):1639-45. PubMed ID: 16639775
    [No Abstract]   [Full Text] [Related]  

  • 15. Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees.
    ; Dixon DO; Freedman RS; Herson J; Hughes M; Kim K; Silverman MH; Tangen CM
    Clin Trials; 2006; 3(3):314-9. PubMed ID: 16895048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Creation of an institutional semi-independent data monitoring committee.
    Tannock LR; Barton-Baxter M; Stoops WW
    Clin Trials; 2019 Oct; 16(5):523-530. PubMed ID: 31257918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Data monitoring committees-state of the art and perspectives for the future].
    Fischer T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 Dec; 63(12):1511-1518. PubMed ID: 32897407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Data monitoring and safety committees and their operations.
    Rouse DJ
    Obstet Gynecol Surv; 2003 May; 58(5):329-36. PubMed ID: 12719675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Data monitoring in randomized controlled trials: surveys of recent practice and policies.
    Clemens F; Elbourne D; Darbyshire J; Pocock S;
    Clin Trials; 2005; 2(1):22-33. PubMed ID: 16279576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks in Randomized Controlled Trials: Role of Interim Analysis and Data Monitoring Committee.
    Naqvi HA
    J Coll Physicians Surg Pak; 2015 Aug; 25(8):557-9. PubMed ID: 26305298
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.